Nigel, the Fast Track news supports the StressGen/Roche HspE7 partnership rearrangement that StressGen concentrate on the fast-to-market, small market, premium price indications of HPV. Moreover, in the years ahead, when Roche markets the high volume, lower price Genital Warts indication for HspE7, Stessgen still gets event-driven milestone payments and sales-based payments for that.
Also, on the institutional owner front:
Royal Bank of Canada mutual funds has reported that they own more than 10% of SSB shares. On the Fidelity mutual fund front, here is Post #7046708 by Oraccle on stockhouse.ca:
Works for me.
Stressgen investor Fidelity boosts holding
Ms. Kim Flood of Fidelity reports
FIDELITY PURCHASES SHARES OF STRESSGEN BIOTECHNOLOGIES CORP.
Stressgen Biotechnologies investor Fidelity Management, the big U.S. fund manager, has purchased 1,140,200 shares (or 1.89 per cent) of Stressgen Biotechnologies outstanding common stock. Fidelity has control but not ownership of these shares. As a result of the purchase, Fidelity holds 6,694,170 shares (or 11.10 per cent) of Stressgen Biotechnologies outstanding common stock. Fidelity's purchase of Stressgen Biotechnologies outstanding common stock was executed on the Toronto Stock Exchange.
Fidelity fund purchases have been made for investment purposes only and not with the purpose of influencing the control or direction of Stressgen Biotechnologies. The Fidelity funds may, subject to market conditions, make additional investments in or dispositions of securities of Stressgen Biotechnologies, including additional purchases of common stock. Fidelity does not, however, intend to acquire 20 per cent of any class of the outstanding voting or equity securities of Stressgen Biotechnologies.
Heat. |
